SEC Filing · 6-K
Immatics N.V.
IMTXNASDAQEQUITYCurrent
SEC Filing
Company context
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics. Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedIn and Instagram.
Current securities
Historical securities (1)
As-filed source
As filedOpen full document ↗